Von Willebrand factor (vWF) mediates initial platelet adhesion to subendothelial matrix at the sites of vessel injury and protects coagulation factor VIII from premature degradation. Abnormalities in vWF are related to either bleeding or thrombotic disorders. Professor RUAN Chang-geng presented research about the pathophysiology and presentation of vWF. Defects in synthesis, secretion and clearance of vWF are the pathogenesis of the most commonly inherited human bleeding disorder, von Willebrand disease (vWD). Impaired secretion or accelerated clearance of vWF can cause type 1 vWD, whereas enhanced proteolysis of vWF by ADAMTS13 may lead to distinctive type 2A vWD. Although a low vWF level is the prominent feature of vWD patients, the wide range of vWF levels makes the diagnosis more difficult, especially for vWD type 1. In contrast with bleeding tendency associated with low vWF levels, the increased levels and/or the presence of high molecular weight multimers of the adhesion molecule correlates with the risk of thrombosis. The typical presentation, thrombotic thrombocytopenic purpura, is characterized by the accumulation of unusually large and hyperactive vWF multimers in plasma because of defective vWF proteolysis by ADAMTS13. Gene mutations or polymorphisms associating with the increased vWF level and activity may be predictive for thromboembolism. SHEN M (Taipai) reported that vWD is common in Taiwan (China). Over 15 years they found 127 patients: 79, 33 and 15 having type 1, type 2 and type 3 of vWD, respectively. They made a genetic study of type 2 vWD and found various genetic mutations. DING Q (Shanghai) performed molecular analysis of inherited bleeding and thrombotic disorders and identified 103 different mutations of 17 genes, 51.5% of which were new. Seventeen missense mutations were studied by ex vivo expression to characterize the synthesis and secretion of the corresponding recombinant proteins. Most of the mutant proteins were produced normally but not secreted because the impaired folding and/or conformational changes cause their retention or degradation by the quality control system of the secretary pathway. In an amino acid substitution, the transcription and translation of the mutant construct was normal without posttranslational processing. This study unravelled the underlying molecular mechanisms of further deficiencies.
Venous thromboembolism (VTE), caused by a variety of congenital abnormalities and/or conditional changes, is a major complication of patients with cancer in Western countries. However, Sakuma M (Sendai, Japan) reported the results of pulmonary embolism (PE) in 65 181 autopsy cases with cancer in Japan. The incidence of PE was 2.32%, which was lower than that in Western cancer patients. PE was relatively frequent in large cell carcinoma, T hepato-cellular carcinoma and adenocarcinoma; and there was a significant correlation between the incidence rate of tumour PE and the incidence of tumour invasion into large veins. Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by recurrent abortion, thromboses and circulating lupus like anticoagulant (LA). Yamazaki M (Kanazana, Japan) studied the mechanisms of induction of antiphospholipid antibodies (aPL) and found that both ICAM-1 and L-selectin might be involved in the development of thrombosis and morbidity in pregnant patients with APS. In animal APS models, mice that were deficient in E-selectin did not develop any changes in platelet counts, APTT, aPL titre and the percentage of glomerular fibrin deposit. These findings indicate that E-selectin has a key role in the induction of aPL. Schlegel N (Paris, France) discussed the clinical features and mechanisms of APS. In a sample of 1000 patients, 53.1% old cases were "primary" APS (isolated syndrome), the other 46.9% being "secondary" APS -36.2% with systemic lupus erythematosus. Laboratory criteria included not only LA and aPL, but also anti-β2 glycoprotein I antibodies.
She proposed a hypothesis, similar to "heparin induced thrombocytopenia-HIT", for the cellular and molecular mechanisms of thrombosis in patients with APS: namely, interference of the aPL with the function of the coagulation cascade, activation of endothelial cells, activation of platelets and stimulation of platelet aggregation. ZHAO Y (Beijing) measured antithrombin (AT), protein C and protein S activities in a large Chinese sample of 3494 normal individuals and found the prevalence of deficient activity were 2.26%, 1.06% and 1.2%, respectively. He concluded that the prevalence of AT, protein C and protein S activity deficiencies were similar to those reported in other Asian nations, but much higher than those in Caucasians in whom the most important causes of thrombophilia are factor V Leiden mutation and prothrombin gene G20210A mutation. JI S (Suzhou) reported imaging thromboembolism with 99m Tc-SZ21, a humanized antiplatelet glycoprotein III monoclonal antibody F(ab) 2 fragment. 99m Tc-SZ21 could specifically bind to platelets and inhibit platelet aggregation ex vivo. Focal uptake occured in planar images as early as 30 minutes (DVT) and 60 minutes (PE) after the labelled agent had been injected. 99m Tc-SZ21 with its modest affinity and high uptake in DVT and PE should be a promising agent for imaging vascular thrombosis.
HU D (Beijing) chose 14 areas of Chinese mainland to perform an epidemiological study, which was mainly on atrial fibrillation (AF). Ischaemic stroke was the most frequent concomitant condition: the stroke rate of patients with AF was significantly higher than without AF (12.1% and 2.1%, respectively). Most of the patients (98%) did not receive prophylactic anticoagulation and no more than 40% received aspirin. To compare the effects of wafarin to aspirin in the prevention of stroke in AF patients, he randomized 704 nonvalvular patients to receive either wafarin or aspirin. The thromboembolismic events in the aspirin group were significantly more than in wafarin group, which decreased the relative risk by 45%. Wafarin treatment was associated with the higher bleeding rate compared to aspirin, although the major bleeding rate was rather low. These results suggest that wafarin is the best choice in the prevention of thromboembolism for the moderate to high risk AF patients.
Aspirin is currently the most cost effective drug for the secondary prevention of cardiovascular diseases, but treatment failures are relatively common. Aspirin resistance has been used to describe not only an absence of the expected pharmacological effects of aspirin on platelets, but also poor clinical outcomes such as recurrent vascular events in patients treated with aspirin. HAN J (Busan, Korea) investigated the possible mechanisms of aspirin resistance and suggested that measurements of whole blood thromboxane B 2 (TXB 2 ) production and urinary excretion of its metabolite, 11-dehydro-TXB 2 , are more specific tests. Clopidogrel is an ADP receptor antagonist, showing superior effectiveness and safety than aspirin. However, some patients do not respond optimally to clopidogrel, referred to as clopidogrel resistance. Nishikawa Y (Tokyo, Japan) reported that a new ADP receptor antagonist, prasugrel, is ten times more potent and has more rapid onset of action than clopidogrel. A phase II b study (n=900) determined that prasugrel had a similar rate of major bleeding to that of clopidorel and a trend towards fewer cardiac events. Prasugrel is currently in phase III registration trial, which will determine if it results in improved outcomes.
Li M (Hong Kong, China) reported that H 2 O 2 increased apoptotic rate of rat cerebral microvascular endothelial cells. This action could be inhibited in a dose-dependent manner by several active ingredients of Chinese herbal medicines such as Salvia miltiorrhiza, which are often used for prevention and treatment of atherosclerosis and cardiovascular disorders. The results of Western blotting showed that H 2 O 2 induced caspase 3 and caspase 9 activation, which were depressed by pretreatment with these effective compounds. This study helps to understand the mechanism of Chinese herbal medicine for treating thrombotic diseases.
The infusion of bone marrow cells into the damaged brain has been proposed as a new clinical practice for this disorder. Thrombopoietin (TPO) is a growth factor for the megakaryocytic lineage. Yan M (Hong Kong, China) identified TPO protein in human cerebrospinal fluid by ELISA, and TPO receptor (c-mpl) mRNA in human cerebral hemispheres and cerebellum. He demonstrated that TPO had a stimulating effect on the in vitro growth of a mouse neural stem cell line C17.2 and that there was significantly less brain atrophy in TPO treated animals when compared with the saline control. His observation further demonstrated an improvement in sensory motor functions after TPO treatment. These findings point to a new strategy for treating brain damage.
HAN Z (Tianjin) explored the feasibility of using blood stem cells in the treatment of sudden, severe limb ischaemia. In an animal experiment, left femoral artery and branches of nude mice were cut to induce unilateral limb ischaemia, and then endothelial progenitor cells (EPCs), which were derived from cord blood CD133 + cells incubated with vascular endothelial growth factor (VEGF), IL-3 and stem cell factor (SCF), were injected via tail vein. The transplanted EPCs were found to survive and incorporate into new capillary network in ischaemic limb. Laser Doppler perfusion imaging showed the blood perfusion ratio and the density of capillaries of ischaemic limb in EPCs group were significantly higher than those of the HUVES and medium groups. Transplantation of EPCs improved the limb salvage.
In clinical trial, patients with arteriosclerosis obliterans of lower extremities or with diabetic food were treated by transplanting G-CSF mobilized peripheral blood stem cells. A significant amelioration of clinical symptoms was observed with improvement of the ankle brachial pressure index, local blood flow, laser Doppler blood perfusion and the angiographic scores. These data indicate that blood stem cell transplantation is a novel, simple, safe and effective therapy for sudden, severe limb ischaemia.
The prospect for gene transfer therapy to cure haemophilia A and B has been proven in principle in haemophilia B dogs utilizing an adeno-associated virus (AAV) transgene strategy. CHEN F (Changsha) performed in vitro and in vivo tests to determine the suitability of gut epithelium for gene transfer, protein secretion of coagulation factor IX. In their studies, factor IX could be secreted both in vitro and in vivo, the qualities at peak were (98±4) ng·10 6 cell·24h and (23.06 ± 1.68) ng/ml, respectively; and its biological activities were (21.23±3.21)% and (23.54 ±2.87)%. DNA, histopathological and histochemical analysis indicated that gene therapy was safe. These results showed that gut epithelial cells might be a reasonable target for gene therapy of haemophilia by a noninvasive route of administration.
All the participants were impressed with the quick development in fundamental and clinical research of the bleeding disorders and thrombotic diseases in recent years on Chinese mainland. However, we must realize that there are still gaps in new lines of investigation and advanced techniques between us and developed countries. This congress provided us a unique opportunity for scientific exchange and academic cooperation with scientists from the Asian Pacific region and elsewhere by promoting all the trends and prospects in our research and development of thrombosis and haemostasis.
WANG Zhao-yue
Jiangsu Institute of Haematology First Affiliated Hospital of Suzhou University Suzhou 215006, China Email: w950831@public1.sz.js.cn (Received October 16, 2006) Edited by SUN Jing
